What’s Ahead for 2024?

As we dive into 2024, we asked our ADVI experts what they think the most compelling or anticipated healthcare issues will be this year. From a continued emphasis on the Inflation Reduction Act (IRA) to upcoming launches in cell and gene therapy, challenging payer dynamics, greater challenges for patient access, and cell and gene therapy access model updates, there is much to look forward to this year.

Michael Beebe, executive vice president of ADVI’s Coding and Reimbursement team, discusses his predictions for 2024 including reimbursement for digital therapeutics and the No Pain Act.
Lauren Feldman, solution leader of ADVI’s Market Access Precision Medicine team, discusses her predictions for LDT test regulation, genetic testing, and Alzheimer’s Disease testing in 2024.
ADVI Health’s CEO and President, Marc Samuels, shares his thoughts on the IRA as we head into 2024.
Sarah Butler, chief commercial officer of ADVI Health, shares her insights on payer dynamics and how life sciences companies will demonstrate value to payers in 2024.
Caitlin Sheetz, solution leader for the ADVI Strategic Analytics, Value and Economics team, discusses her take on what to expect in 2024 regarding novel therapies and real-world evidence.
Josh Greenblatt, senior vice president of ADVI’s Market Access team, discusses his predictions for patient access challenges in 2024.
Alicia Silver, director of ADVI’s Value, Access and Pricing team, discusses upcoming updates to the Cell and Gene Therapy Access Model.

Learn More

Stay ahead of the curve this year. Get in touch today to gain expert insights and strategic counsel on the evolving healthcare landscape.

Interested in getting in touch with Melyssa?

Melyssa Nocar

Head of Marketing